The present postmarketing surveillance (PMS) study is the first large scale systematic and prospective clinical trial of pharmacotherapeutic intervention in advanced stages of dementia. Within a validation program this study aimed at demonstrating the sensitivity of the D-Scale of change (DS-C) for measuring ADL-function. Efficacy of treatment with the NMDA-antagonist memantine[1] was investigated in 531 patients with advanced dementia employing a parallel group design that stratified patient cohorts by severity according to GDS stages (Reisberg, 1992). Efficacy was determined on two independent levels: by the assessment of the physicians' Clinical Global Impression of Change (CGI-C) at the end of a 6-week observation period, and by the assessment of change in elementary ADL-functions by the caregivers using the D-Scale-of-Change. With the D-Scale-of-Change the caregivers can assess a change in broad functional items, i.e. cognitive and motor functions and also elementary functions of daily life. The effect size of this improvement increased constantly during the observation period. Even in patients of GDS stage 7 an improvement could be measured. These results were also seen by the physicians, who recorded an overall clinical improvement in 75.5 % of the patients after 6 weeks. Tolerability evaluations resulted in the ratings “very well” by 59.5 % or “well” by 35.0 % of the patients. No serious adverse drug reactions occurred. A correlation analysis demonstrated a high congruency of both assessments. Furthermore, the observed time course of these improvements paralleled with the time course of symptomatic benefit by effects of memantine that had been repeatedly demonstrated in randomised, double-blind, placebo-controlled studies in mild to moderate dementia. Together with the evaluation of the scale-properties of the D-Scale for assessment of severity the D-Scale and the D-Scale-of-Change can be regarded as validated.
1 Memantine = 1-amino-3,5 dimethyladamantane
References
1 Arnold K, Lehfeld H, Mösler Th, Erzigkeit H. Scale properties of the D-Scale in severe dementia. 6th Int. Conf. Alzheimer's Disease. Amsterdam; 1998
7
Galasko D, Bennett M, Sano M. et al .
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease.
Alzheimer Dis. Assoc. Disorders.
1997;
11,Suppl. 2
33-39
12 Kam P, Mol F, Wimmers M FMG. Beurteilungsskalen für geriatrische Patienten (BGP) (CIPS) Internationale Skalen für Psychiatrie, 4. Auflage. Beltz Test Göttingen; 1996
14
Misztal M, Frankiewicz T, Parsons C G, Danysz W.
Learning deficits induced by chronic intraventricular infusion of quinolinic acid - protection by MK-801 and memantine.
European Journal of Pharmacology.
1996;
296
1-8
15
Pantev M, Ritter R, Görtelmeyer R.
Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment.
Zeitschrift für Gerontopsychologie und -psychiatrie.
1993;
6
103-117
16
Parsons C G, Danysz W, Quack G.
Memantine is a clinically well tolerated NMDA Receptor Antagonist - a review of preclinical data.
Neuropharmacology.
1999;
38
735-767
17
Reisberg B, Ferris S H, de Leon M Y, Crook T.
The global deterioration scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD).
Am. J. Psychiat..
1992;
139
1136-1139
18 Rüther E, Glaser A. The NMDA-antagonist memantine in severe dementia: Results of a prospective post-marketing surveillance study. 6th Int. Conf. Alzheimer's Disease Amsterdam; 1998
19
Seif el Nasr M, Peruche B, Roßberg C, Mennel H D, Krieglstein J.
Neuroprotective effect of memantine demonstrated in vivo and in vitro.
Eur. J. Pharmacol..
1990;
185
19-24
